SunTrust Banks set a $127.00 price target on Celgene (NASDAQ:CELG) in a research report report published on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on CELG. BMO Capital Markets upped their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an outperform rating in a research report on Friday, November 17th. Oppenheimer restated a buy rating and set a $170.00 price target on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a buy rating to a strong-buy rating and set a $144.39 price target for the company in a research report on Monday, October 23rd. Cann restated a buy rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an underweight rating to an equal weight rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $131.35.

Shares of Celgene (NASDAQ:CELG) traded up $1.31 during trading hours on Monday, hitting $105.49. 7,162,280 shares of the company’s stock were exchanged, compared to its average volume of 7,625,340. The firm has a market capitalization of $83,050.00, a PE ratio of 24.88, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 earnings per share. sell-side analysts predict that Celgene will post 6.68 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its position in shares of Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares in the last quarter. BlackRock Inc. lifted its position in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new stake in shares of Celgene in the second quarter worth approximately $271,605,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. 79.74% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/celgene-celg-given-a-127-00-price-target-at-suntrust-banks/1800151.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.